Clinical Trials

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01424982 2026-04-15

Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia

88 enrolled

Blast Crisis, Leukemia, Myeloid, Accelerated Phase, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04747912 2026-03-30

Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)

Phase 2 Suspended

25 enrolled

Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06207123 2026-03-18

A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)

Phase 1/2 Recruiting

15 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02467270 2026-03-17

OPTIC

283 enrolled 31 charts

Bone Marrow Diseases, Hematologic Diseases, Leukemia, Leukemia, Myeloid, Myeloproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT01746836 2026-03-09

Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib

Phase 2 Recruiting

50 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT05306301 2026-03-06

Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients

32 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05268003 2026-03-05

A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia

26 enrolled

Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03263572 2026-02-25

Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia

Phase 2 Recruiting

90 enrolled

Blast Crisis, Leukemia, Myeloid, Accelerated Phase, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03147612 2026-02-17

Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia

22 enrolled

Blast Crisis, Leukemia, Myeloid, Accelerated Phase, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06860269 2026-02-10

GRAALL-2024

Phase 2/3 Recruiting

1,200 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01570868 2025-12-08

Ponatinib - Frontline for Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP)

51 enrolled 8 charts

Phase 3 Active not recruiting

Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03589326 2025-11-26

A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia

245 enrolled 15 charts 2 FDA

Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)

NCT04188405 2025-11-20

Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia

20 enrolled

Blast Crisis, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Acute

NCT04070443 2025-11-18

TIPI

170 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT06390306 2025-06-03

The Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients With CML-MBP

Recruiting

30 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03576547 2025-05-08

Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia

Phase 1/2 Terminated

9 enrolled 11 charts

Blast Crisis, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06945146 2025-04-25

CAP

Completed

65 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT04233346 2025-04-04

The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation

93 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03690115 2025-03-25

PONALLO

Other hematologic neoplasm

23 enrolled

Leukemia, Myeloid, Acute

NCT04722848 2025-01-23

Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL

Phase 3 Active not recruiting

236 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02398825 2025-01-17

Activity and Risk Profile of Ponatinib in Chronic Phase Patients With Chronic Myeloid Leukemia Resistant to Imatinib

14 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT04160546 2024-12-31

ResToP

80 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT04475731 2024-10-22

Ponatinib in Adult Ph+ ALL Patients With MRD Positivity or Hematological Relapse

67 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04554459 2024-08-14

Pona-CELL

4 enrolled

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

2 enrolled

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT04845035 2024-02-22

Pediatric-Inspired Chemotherapy Plus Tyrosine Kinase Inhibitor in Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Phase 2 Withdrawn

Philadelphia Chromosome, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06175702 2023-12-19

LALPh2022

Not yet recruiting

150 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05286528 2023-10-27

Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund Database

Completed

1,484 enrolled 6 charts

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03807479 2023-09-14

PONS

18 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT03709017 2022-12-07

Iclusig PMS in CML or Ph+ALL Patients

Unknown

50 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02448095 2022-10-26

Retrospective Evaluation of CML Patients in the National Compassionate Program

Terminated

38 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01667133 2022-06-13

A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL)

Phase 1/2 Completed

35 enrolled 36 charts

Bone Marrow Diseases, Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Leukemia, Myeloid, Lymphatic Diseases, Lymphoproliferative Disorders, Myeloproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01641107 2021-11-30

LAL1811

44 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02627677 2021-11-26

OPTIC-2L

Phase 3 Terminated

44 enrolled 22 charts

Bone Marrow Diseases, Hematologic Diseases, Leukemia, Leukemia, Myeloid, Myeloproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT01620216 2021-11-04

Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia

12 enrolled 12 charts

Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04709731 2021-02-03

CarPAs

Phase 2 Unknown

50 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01207440 2021-02-02

PACE

449 enrolled 28 charts

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT04688983 2020-12-30

EWALL-Ph-03

Phase 2 Unknown

180 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02779283 2020-05-26

Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia

Phase 1 Completed

7 enrolled

Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04043676 2019-08-02

Consolidation Treatment With Ponatinib 15 mg on Treatment Free-Remission Rate in Patients With Chronic Myeloid Leukemia

Phase 2 Unknown

40 enrolled

Bronchiolitis Obliterans Syndrome, Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00660920 2018-05-16

Safety Study of AP24534 to Treat Chronic Myelogenous Leukemia (CML) and Other Hematological Malignancies

Phase 1 Completed

81 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Hematologic Neoplasms

NCT01592136 2018-02-06

Expanded Access Program of Ponatinib

Approved for marketing

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03331211 2017-11-08

Observation of the Effect of Chemotherapy Combined With Tyrosinase Inhibitor on the Reactivation of CMV and EBV in Patients With Acute Lymphoblastic Leukemia

Unknown

100 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02829840 2017-06-02

Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML)

Phase 1/2 Withdrawn

Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT02981784 2016-12-05

Comparative Evaluation of Results of Allogeneic Hematopoietic Stem Cells Versus Ponatinib in CML Patients Carrying a Mutation T315I

Completed

184 enrolled

Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01650805 2014-11-17

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Phase 3 Terminated

307 enrolled 11 charts

Bone Marrow Diseases, Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Leukemia, Myeloid, Lymphatic Diseases, Lymphoproliferative Disorders, Myeloproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01549548 2013-03-15

Compassionate Use Ponatinib

No longer available